Sugi Predict

Sugi Predict / Compounds / SCHEMBL1781465

SCHEMBL1781465

SCHEMBL1781465

FC(F)(Br)c1ccc(Br)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 4/20 0.50
▸ CA1 P00915 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ CA5A P35218 1/20 0.50
▸ CYP2A6 P11509 1/20 0.50
▸ ALDH1A1 P00352 4/20 0.38
▸ ALOX15 P16050 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ TRPV1 Q8NER1 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.35
▸ TSHR P16473 1/20 0.33
▸ CES2 O00748 1/20 0.33
▸ CES1 P23141 1/20 0.33
▸ AHR P35869 1/20 0.33
▸ OGG1 O15527 1/20 0.32
▸ CA12 O43570 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL927399 0.87 ALDH1A1 (0.37) CA2CA1CA9CA5AALDH1A1
SCHEMBL21791779 0.81 CA1 (0.50) CA2CA1CA9CA5ACYP2A6
SCHEMBL8909 0.81 TRPV1 (0.50) CA2CA1CA9CA5ACYP2A6
SCHEMBL3675742 0.81 CA1 (0.50) CA2CA1CA9CA5ACYP2A6
SCHEMBL1729090 0.79 TRPV1 (0.48) CA2CA1CA9CA5ACYP2A6
SCHEMBL13205250 0.78 ALDH1A1 (0.53) ALDH1A1TSHRCES2CES1
SCHEMBL17996511 0.77 CA2 (0.52) CA2CA1CA9CA5ACYP2A6
SCHEMBL5239662 0.77 CA1 (0.46) CA2CA1CA9CA5ACYP2A6
SCHEMBL13526 0.77 CA1 (0.46) CA2CA1CA9CA5ACYP2A6
SCHEMBL21995400 0.77 CA1 (0.46) CA2CA1CA9CA5ACYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590062-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2026-03-31 — — US disclosed
US-20250333429-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS INC (US) 2025-10-30 — — US disclosed
EP-4622981-A1 MODULATORS OF TNF-ALPHA ACTIVITY Forward Therapeutics, Inc. (US) 2025-10-01 — — EP disclosed
US-12384808-B2 Modulators of TNF-α activity FORWARD THERAPEUTICS, INC. (US) 2025-08-12 — — US disclosed
CN-118693282-B Secondary battery and preparation method and application thereof 蜂巢能源科技股份有限公司 2024-12-03 — — CN disclosed
CN-118693282-A Secondary battery and preparation method and application thereof 蜂巢能源科技股份有限公司 2024-09-24 — — CN disclosed
US-20240247014-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. 2024-07-25 — — US disclosed
WO-2024112796-A1 MODULATORS OF TNF-α ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2024-05-30 — — WO disclosed
US-20230099421-A1 A NEW METHOD OF 18F LABELLING AND INTERMEDIATE SALTS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2023-03-30 — — US disclosed
EP-4026835-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2022-07-13 — — EP disclosed
US-7329777-B2 Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis BAYER AKTIENGESELLSCHAFT (DE) 2008-02-12 — — US disclosed
EP-1845147-A2 Liquid-crystalline compounds Merck Patent GmbH (DE) 2007-10-17 — — EP disclosed
WO-2007045366-A1 HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2007-04-26 — — WO disclosed
WO-2007045366-A1 HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2007-04-26 — — WO disclosed
US-20050288366-A1 Novel aminodicarboxylic acid derivatives BAYER AKTIENGESELLSCHAFT (DE) 2005-12-29 — — US disclosed
US-6939990-B2 Derivatives of dicarboxylic acid having pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2005-09-06 — — US disclosed
US-20040110840-A1 Novel derivatives of dicarboxylic acid having pharmaceutical properties BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-06-10 — — US disclosed
EP-1368302-A1 NOVEL AMINO DICARBOXYLIC ACID DERIVATIVES Bayer Aktiengesellschaft (DE) 2003-12-10 — — EP disclosed
WO-2002070459-A1 NOVEL AMINO DICARBOXYLIC ACID DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2002-09-12 — — WO disclosed
US-5589102-A Benzene derivatives, and liquid-crystalline medium MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1996-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384808-B2 Modulators of TNF-α activity TNF, NFKBIA, TNFRSF1A CA2 4692/4885CA1 4471/4885CA9 4695/4885
US-20040110840-A1 Novel derivatives of dicarboxylic acid having pharmaceutical properties SDHA, GOT2, MDH2 CA2 84/4885CA1 527/4885CA9 305/4885
US-12590062-B2 PD-1/PD-L1 inhibitors CD274, PDCD1LG2, PDCD1 CA2 3359/4885CA1 2733/4885CA9 526/4885
US-20230099421-A1 A NEW METHOD OF 18F LABELLING AND INTERMEDIATE SALTS NPY1R, TMEM14C, SLCO1B1 CA2 2394/4885CA1 590/4885CA9 622/4885
US-20050288366-A1 Novel aminodicarboxylic acid derivatives DDC, DAO, AADAT CA2 2245/4885CA1 3885/4885CA9 1589/4885
US-20250333429-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, NFKBIA, TNFRSF1A CA2 4673/4885CA1 4258/4885CA9 4697/4885
US-20240247014-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, NFKBIA, TNFRSF1A CA2 4673/4885CA1 4258/4885CA9 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.